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Purpose: This paper proposed to evaluate the tear fluid mucin 5AC (MUC5AC) change in Chinese primary angle-closure
glaucoma and cataract patients after short-term medications and phacotrabeculectomy.
Methods: Twenty-five eyes of 25 consecutive Chinese patients with coexisting visually significant cataract and angle-
closure glaucoma and 40 eyes of 40 volunteers enrolled in this study were investigated. Tear fluid from normal subjects
and patients  (1 day pre-operatively, 1 month, 3 months, and 6 months post-operatively,  respectively)  were collected.
The MUC5AC protein levels in the tear fluid were determined by Enzyme-Linked ImmunoSorbent Assay (ELISA). The
MUC5AC change after phacotrabeculectomy was evaluated.
Results: The MUC5AC quantity of the patients after short-term medications was 16.95±12.86 ng/ml, compared with
32.39±18.44 ng/ml MUC5AC quantity of the controls. There was a significant difference between the two groups (p<0.05).
The MUC5AC of the patients decreased significantly to 6.91±7.11 ng/ml at 1 month after surgery (p<0.05). At 3 months
after surgery, the MUC5AC recovered to 15.53±12.63 ng/ml, and had no significant difference with the pre-operative
level (p=0.26). At 6 months after surgery, the MUC5AC was 18.94±14.64 ng/ml and had no significant difference with
before-surgery levels (p=0.14).
Conclusions: Both phacotrabeculectomy and short-term anti-glaucoma medications can decrease the MUC5AC in the
tear fluid of primary angle-closure glaucoma patients. At 3 months after phacotrabeculectomy, the MUC5AC could recover
to the pre-operative level. More attention should be paid to the tear film stability and ocular surface physiology in these
patients.
The preocular film is composed of a thin outer layer of
Meibomian lipids and an inner aqueous phase adjacent to the
glycocalyx of the apical cells of the epithelium. Epithelial
mucins, a family of high-molecular-weight glycoproteins, are
the major protein components of the aqueous phase of the tear
fluid  [1,2].  Mucins  have  been  ascribed  several  roles:
maintaining a smooth surface for light refraction, lubricating
the eyelids, the conjunctiva and the cornea, supplying the
cornea with nutrients and removing foreign materials from the
cornea and conjunctiva. Mucins can also participate in the
defense of the ocular surface via specific and nonspecific
antibacterial substances [3].
The  ocular  surface  epithelium  expresses  at  least  four
major mucin genes: MUCIN 1 (MUC1), MUCIN 4 (MUC4),
MUCIN  5AC  (MUC5AC),  and  MUCIN  16  (MUC16).
MUC1, as a transmembrane mucin, is reported to be produced
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by the corneal and conjunctival epithelia [4,5]. MUC4, also a
transmembrane mucin, is expressed by corneal as well as
conjunctival  epithelia.  Although  MUC4  is  present  in  the
cornea,  the  expression  of  MUC4  mRNA  has  been
demonstrated in limbal and peripheral cornea, with decreasing
levels toward the central cornea [6,7]. MUC16, also known as
the CA125 antigen, is also a membrane-associated mucin
expressed by the ocular surface. MUC16 is a key component
of the ocular surface glycocalyx, where plays a role in barrier
formation on the surface of epithelial cells [8]. MUC5AC is a
gel-forming secretory mucin expressed by conjunctival goblet
cells. MUC5AC is the main mucin component of the tear film
[7,9,10].
The negative effects of anti-glaucomatous medications
on the ocular surface have been known from previous studies
and reports. In short, ocular surface disease (OSD) is prevalent
among medically treated patients with glaucoma; intraocular
pressure (IOP)-lowering medications can contribute to OSD,
in  part  due  to  the  preservatives  used  in  medications;  the
severity of OSD symptoms is positively correlated to the
duration  and  number  of  IOP-lowering  medications  used
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2342[11-14]. However, there is few studies concerning the ocular
surface change of glaucoma patients induced by surgery.
In  the  present  study,  we  evaluated  the  quantity  of
MUC5AC  in  the  tear  fluid  of  patients  with  glaucoma
combined with cataract after the use of topical anti-glaucoma
medications  for  less  than  6  months,  and  monitored  the
MUC5AC change of the patients after phacotrabeculectomy.
METHODS
Patients and volunteers: This study adhered to the tenets of
the Declaration of Helsinki. This study was approved by the
ethics committee of Tianjin Medical University Eye Center,
Tianjin, China. Written, informed consent was obtained from
all  primary  angle-closure  glaucoma  (PACG)  patients  and
volunteers.  The  diagnosis  of  PACG  was  made  based  on
elevated  IOP,  a  shallow  anterior  chamber,  gonioscopic
findings of synechia, glaucomatous optic disc cupping, and
the Humphrey visual field defects. The inclusion criteria for
the study group were: (1) PACG and coexisting cataract in the
same eye; (2) anti-glaucoma eye drops administered for less
than 6 months. The inclusion criteria for the control group
were:  (1)  the  company  of  the  patients  who  were  not
administered any eye drops; (2) able and willing to give an
informed consent to take the tear fluid sample. The exclusion
criteria for both the study group and the control group included
a  history  of  disease  that  could  affect  the  ocular  surface
(blepharitis, dacryocystitis, keratoconjunctivitis sicca, etc),
contact lens wearing and previous ocular surgery or systemic
disease, such as diabetes mellitus.
Sample  collection:  Tear  fluid  from  normal  subjects  and
patients (1 day pre-operatively, 1 month, 3 months, and 6
months  post-operatively,  respectively)  were  collected  to
determine MUC5AC protein levels. At least 5 μl open eye
tears  were  collected  from  the  outer  canthus  of  patients/
volunteers using glass capillary tubes. No anesthetic or other
medication was applied. The glass capillary tube was not
allowed to touch either the lid or any part of the globe. The
collected tear fluid was stored in −20 °C for further analysis.
Enzyme-Linked ImmunoSorbent Assay (Elisa): The rat anti-
human  Mucins  5ac  Elisa  kit  (Diagnostic  Systems
Laboratories, Webster, TX) was used and the procedure was
conducted as the introduction book indicated as follows. First,
the standard curve was made using the standard samples (25,
50, 100, 250, and 500 pg/ml). Then 5 μl tear fluid sample was
diluted to 1:40 with diluted sample dilution, and then 100 μl
diluted samples were transferred into the appropriate wells.
After incubation for 30 min at 37 °C,the wells were aspirated
and  washed  5  times  with  the  diluted  wash  buffer;  then
100  μl  enzyme  conjugate  was  added  to  each  well.  The
incubation (37 °C for 30 min) and aspiration/wash procedure
was repeated. Followed by incubation for 15 min at 37 °C,
50 μl Color Reagent A and Color Reagent B were added to
each well. Finally 50 μl Stop solution was added to each well.
The  absorbance  and  the  MUC5AC  concentration  of  the
solution in the wells were recorded within 15 min. The ELISA
was performed in duplicates for each tear fluid sample and the
average was recorded as the final result.
Surgical  procedure:  All  the  patients  accepted  two-site
phacotrabeculectomy  performed  by  the  same  experienced
surgeon (J.J.). The pupil was dilated with 0.5% tropicamide
drops (Shuanghe Co., LTD, Beijing, China) 30 min before
surgery. All the surgeries were made under peribulbar local
anesthesia  with  2%  lidocaine  (Jinyao  Co.,  LTD,  Tianjin,
China). Ocular compression was performed in every case. A
fornix-based conjunctival flap was fashioned at the 12 o’clock
position. The 1/2 thickness rectangular scleral flap (3×4 mm)
was performed with a crescent knife. A sponge soaked with
0.2 mg/ml mitomycin-C (MMC; Haizheng Pharmaceutical
Co., Zhejiang , China) was applied under the conjunctival flap
for 2 min, and the area was washed out with a balanced salt
solution. A small limbal paracentesis was performed at the 2
o’clock position. The anterior chamber was then entered along
the corneal tunnel with the 3.0-mm keratome at the 10 o’clock
position.  The  chamber  was  immediately  deepened  with
Viscoat  (S.A.  Alcon-Couvreur  N.V.,  Rijksweg,  Puurs,
Belgium). Pupil stretching or synechiolysis were performed
when  necessary.  After  the  continuous  curvilinear
capsulorhexis, the nucleus was removed with a standard four-
quadrant,  “divide  and  conquer”  technique.  An  automated
irrigation/aspiration apparatus (Alcon Laboratories, Inc., Fort
Worth,  TX)  was  introduced  into  the  anterior  chamber  to
remove the cortical remnants and to polish the posterior lens
capsule. The intraocular lens (IOL) was placed in the capsular
bag. The pupil was contracted with 0.01% carbachol injection
(Bausch & Lomb Freda, Jinan, Shandong, China). The scleral
flap  was  then  dissected  forward  into  the  clear  cornea.  A
trabeculectomy of 1×2 mm was performed with a 15° scalpel
and Vannas scissors. A peripheral iridectomy was performed,
which was basally large enough to be sure that the iris could
not be visualized in the base of the trabeculectomy opening.
The rectangular scleral flap was closed with two 10/0 nylon
sutures at the apex angles. The conjunctival wound was closed
with two 10/0 nylon sutures.
Post-operative  care  and  follow-up:  Post-operative
medications employed routinely are 0.3% ofloxacin drops
(Santen, Osaka, Japan) six times per day, 1% fluorometholone
drops (Santen) six times per day, and 0.1% diclofenac sodium
drops  (Xingqi  Pharmaceutical  Co.,  LTD,  Shenyang,
Liaoning,  China)  four  times  per  day.  All  the  drops  were
stopped after 4 weeks of treatment and steroids were tapered
off during the 4 weeks. All the patients required no anti-
glaucoma medications after surgery. The tear fluid of the
patients was collected on months 1, 3, and 6 post-operatively.
Statistical  analysis:  Data  was  reported  as  Mean±SD.  All
analyses  were  performed  with  SPSS  (IBM,  Somers,  NY)
software version 13.0. Independent samples t test was used
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volunteers. The χ2 test was used for the comparison of gender
between patients and volunteers. Paired samples t test was
used for the pre-operative and post-operative comparisons of
MUC5AC. A p<0.05 was considered statistically significant.
RESULTS
Patients  and  controls:  Twenty-five  consecutive  Chinese
patients  with  coexisting  visually  significant  cataract  and
PACG were enrolled as the study group. Forty volunteers
were enrolled as the control group. No subjects refused to
enroll and none were lost to follow-up during the course of
the study. There were no statistical differences between the
two groups regarding age (67.4±10.1 years versus 65.0±9.8
years, independent samples t test, t=0.94, p=0.35) or gender
(χ2 test, χ2=0.19, p=0.66).
Pre-operative anti-glaucoma medications: All the patients
were administered at least one of the four anti-glaucoma eye
drops for less than 6 months before surgery: 2% Carteolol
hydrochloride (Mikelan; Otsuka Pharmaceutical Co., LTD,
China), 1% Brinzolamide eye drops (Azopt; Alcon), 0.2%
Brimonidine Tartrate eye drops (Alphagan; Allergan, Mayo,
Ireland),  1%  Pilocarpine  nitrate  eye  drops  (Yongguang
Pharmaceutical Co., LTD, Sanhe, Hebei, China). There were
3 patients administered 2% Mikelan alone, 1 patient Alphagan
alone, 11 patients 2% Mikelan and Azopt, 2 patients 2%
Mikelan  and  1%  Pilocarpine,  1  patient  2%  Mikelan  and
Alphagan,  and  7  patients  2%  Mikelan  and  Azopt  and
Alphagan.
MUC5AC  quantity  of  the  patients  and  controls:  The
MUC5AC quantity of the patients detected by ELISA was
16.95±12.86  (range  from  1.36  to  43.79)  ng/ml,  and
32.39±18.44 (range from 4.05 to 73.16) ng/ml of the controls.
There was a significant difference between the two groups
(independent samples t test, t=3.66, p<0.05).
MUC5AC change of the patients after phacotrabeculectomy:
The MUC5AC changes after phacotrabeculectomy are shown
in  Table  1.  The  MUC5AC  decreased  significantly  from
16.95±12.86 ng/ml before surgery to 6.91±7.11 (range from
1.11 to 27.37) ng/ml 1 month after surgery (paired samples t
test, t=4.93, p<0.05). At 3 months after surgery, the MUC5AC
recovered to 15.53±12.63 (range from 1.23 to 47.47) ng/ml,
and had no significant difference with the pre-operative level
(paired samples t test, t=1.15, p=0.26). At 6 months after
surgery, the MUC5AC detected by ELISA was 18.94±14.64
(range from 1.30 to 49.66) ng/ml, and had no significant
difference with the MUC5AC before surgery (paired samples
t test, t=-1.54, p=0.14).
DISCUSSION
In  our  study,  by  using  ELISA,  we  have  demonstrated  a
significant reduction of MUC5AC mucin protein content on
the ocular surface of PACG patients who accepted short-term
topical  medication  treatment.  For  MUC5AC,  which  is
secreted solely by conjunctival goblet cells, this indicates that,
even  for  a  relatively  short-term  topical  anti-glaucoma
medication therapy, the goblet cells of the patients may be
decreased considerably, numerically and/or functionally. One
of  the  reasons  for  the  reduction  of  MUC5AC  is  the
preservatives used in the anti-glaucoma medications. Several
studies have reported toxic side effects from anti-glaucoma
drugs on the conjunctiva, especially if preservatives are used
[15-17].  The  toxic  action  of  preservatives  on  the  ocular
surface has been widely demonstrated in vitro as well as in
vivo, in both humans and animals [18]. Preservatives can
decrease  the  stability  of  the  precorneal  film,  directly  or
indirectly. They have a direct detergent effect on the lipid
layer, resulting in increased evaporation. Preservatives can
also decrease the density of goblet cells in the conjunctival
epithelium, which will decrease the MUC5AC content in the
tear, and indirectly, destabilize the tear film [19]. By new
combined  tools,  Pauly  et  al.  [20]  detected  a  significant
MUC5AC positive goblet cells loss induced by preservatives;
Albietz et al. [21] also detected a reduced goblet cell density
in dry eye receiving preserved topical agents. Another reason
for  the  reduction  of  MUC5AC  includes  the  multiple
treatments of the patients in our study. Histopathological and
impression  cytology  studies  of  the  conjunctiva  have
demonstrated  that  topical  preservatives  can  lead  to
inflammation,  squamous  metaplasia,  and  subconjunctival
fibrosis in the conjunctiva and Tenon’s capsule [19,22]. These
side effects are dose dependent and increase with frequency
of instillation [18]. Moreover, the increasing preservatives
concentrations can also induce an enhanced apoptosis rate of
the conjunctival epithelial cells [20]. In our study, only 4
patients were administered single anti-glaucoma medication
TABLE 1. MUC5AC AFTER PHACOTRABECULECTOMY (NG/ML).
  Preop 1 Month 3 Months 6 Months
MUC5AC 16.95±12.86 6.91±7.11 15.53±12.63 18.94±14.64
t   4.93 1.15 −1.54
p   <0.05 0.26 0.14
        The MUC5AC decreased significantly at 1 month after surgery and recovered at 3 months after surgery. In the table, Preop:
         pre-operatively; 1 month: 1month post-operatively; 3 months: 3 months post-operatively; 6 months: 6 months post-operatively.
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2344treatment;  most  of  the  patients  (21/25)  accepted  multiple
treatments. The multi-use of anti-glaucoma medication will
increase  the  above  dose  dependent  toxic  action  of  the
preservatives on the conjunctiva and lead to the decrease of
MUC5AC level.
Rodriguez et al. [23] showed a decrease in goblet cell
populations until the third month after LASIK by impression
cytology, which was highly correlated with suction time. Li
et al. [24] revealed significant reduction of goblet cell density
and  the  presence  of  serious  squamous  metaplasia  in  the
epithelial layer of the globe conjunctiva at 3 months after
cataract surgery. In our study, we also detected a decrease of
MUC5AC in the tear fluid after phacotrabeculectomy, which
probably resulted from the conjunctival squamous metaplasia
and the reduction of goblet cell density, for MUC5AC of the
tear fluid is secreted uniquely by the conjunctival goblet cells.
The reduction in goblet cell density can be due to several
factors such as toxicity of MMC introduced during the surgery
and post-operative topical medication, damage of the corneal
and  conjunctival  nerves  and  the  limbus  stem  cells,
inflammation, or mechanical trauma produced by the surgery
[23]. In this study, we found the MUC5AC recovered to the
pre-operative level at 3 months after surgery. This might have
resulted from an adapted response against the conjunctival
aggression [6], for there are numerous typical MUC5AC-
positive goblet cells outside the edges of the filtering blebs,
proved by impression cytology [25].
As the main mucin component of the tear film, MUC5AC
is believed to play an important role in attainment of tear
stability and in prevention of drying on the ocular surface
[3]. The decrease in the amount of mucin molecules on the
ocular surface will affect the stability of the tear film and
compromise the normal ocular surface physiology; patients
will feel more sensitive to environmental factors because the
eye’s protective function is weakened [1]. In our study, we
demonstrated a significant decrease of MUC5AC in the tear
fluid  of  PACG  patients  after  short-term  anti-glaucoma
medications or phacotrabeculectomy, and this indicates that,
for  these  patients,  more  attention  should  be  paid  to  the
maintenance or recover of their tear film stability and ocular
surface physiology.
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